查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2085450

糖尿病注射筆市場：依產品類型、技術、療法、最終用戶和通路分類－2026-2032年全球市場預測

Diabetes Injection Pens Market by Product Type, Technology, Therapy Type, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，糖尿病注射筆市場規模將達到 289.3 億美元，複合年成長率為 6.60%。

主要市場統計數據
基準年 2025 185億美元
預計年份：2026年 196億美元
預測年份 2032 289.3億美元
複合年成長率 (%) 6.60%

隨著醫療系統應對疾病盛行率上升、對強化治療的需求增加以及對更安全的自我給藥方式的需求，糖尿病注射筆正逐漸成為注射胰島素和其他注射型糖尿病藥物的主要平台。國際糖尿病聯盟（IDF）估計，2021年全球有5.37億成年人患有糖尿病，預計到2030年這一數字將達到6.43億，到2045年將達到7.83億，因此，市場對可靠且方便患者使用的注射裝置的需求持續旺盛。

拋棄式胰島素筆、可重複使用胰島素筆、智慧胰島素筆、筆針以及支援劑量精準、用藥依從性和患者信心的訓練體系共同塑造了這個市場。儘管從以診所為中心的護理模式向以家庭為基礎的慢性病管理模式的轉變正在推動其普及，但對於製造商、保險公司、醫療服務提供者和患者而言，價格、保險報銷、低溫運輸物流、處方規範和醫療設備廢棄物處理仍然是決定性因素。

糖尿病注射筆市場發生變革性變化

糖尿病注射筆市場正從傳統的機械裝置轉向以患者為中心的互聯式管理系統。能夠記錄注射時間和劑量的智慧注射筆正日益與持續血糖監測、行動醫療應用程式以及醫療專業人員使用的控制面板整合，從而實現更便捷的糖尿病管理，而無需強制所有患者使用胰島素幫浦。

人工智慧對糖尿病胰島素筆的累積影響。

人工智慧 (AI) 正在為糖尿病注射筆的研發、商業化和使用各個階段帶來累積價值。在互聯醫療領域，AI 驅動的分析功能，結合患者從血糖儀和連續血糖監測儀獲取的數據，可以幫助識別漏服藥物、不規則的用藥模式以及血糖值波動。這些功能可支持更個人化的臨床互動，並且在適當的醫療監督下使用，可以減少治療停滯。

關於糖尿病注射筆的關鍵區域見解

亞太地區是糖尿病胰島素筆最重要的成長市場之一，這主要得益於該地區糖尿病患者數量龐大、中產階級不斷壯大，以及中國、印度、日本、韓國和澳洲等國的糖尿病診斷率不斷上升。國際糖尿病聯盟（IDF）指出，西太平洋和東南亞地區擁有全球最高的糖尿病成人患者數量，因此，確保患者能夠獲得胰島素筆、筆針以及接受患者教育至關重要。北美市場依然價值不菲，這得益於先進的內分泌醫學、胰島素類似物和GLP-1療法的廣泛應用、完善的藥品福利管理體係以及智慧糖尿病管理設備的快速普及。

東協、海灣合作理事會、歐盟、金磚國家、七國集團和北約的關鍵集團分析

在東協地區，都市化、私人醫療保健的擴張以及政府為防治非傳染性疾病所做的努力支撐了對糖尿病筆的需求，儘管各成員國之間的價格和保險報銷政策存在顯著差異。在海灣合作理事會地區，糖尿病盛行率高、醫院基礎設施先進、國家層面的數位健康策略以及對支持互聯糖尿病管理的專業醫療模式的投入增加，都表明糖尿病筆在該地區具有很高的普及潛力。

主要國家糖尿病注射筆使用分析

美國的特點是治療方法先進、注射型糖尿病藥物廣泛使用，並注重價格可負擔性、納入醫療保險範圍以及自付費用管理。在加拿大，全民健保原則與各省報銷制度的差異並存。與此同時，墨西哥和巴西的需求正因公共衛生計畫、私營部門的成長以及糖尿病診斷率的上升而不斷成長。在歐洲，英國、德國、法國、義大利和西班牙受益於基於指南的糖尿病護理、系統化的報銷制度和成熟的藥房網路。另一方面，俄羅斯市場則受到本地化、採購政策、進口替代優先事項和供應連續性的影響。

為行業領導者提供的實用建議

產業領導者應優先考慮在價格、易用性、劑量精準度、注射舒適度和數位化連接性之間取得良好平衡的醫療設備組合。企業可以透過投資人體工學、多語言病患教育、醫護人員培訓，以及設計適合老年人和手部靈活性、視力或運算能力受限病患的醫療設備，來加速產品推廣應用。

調查方法

本次高階主管評估基於對公共衛生、監管和行業認可來源的二手研究，包括國際糖尿病盛行率數據、醫療設備指南、報銷趨勢、臨床實踐模式以及已通過核准的注射用糖尿病藥物資訊來源。調查方法強調從流行病學、技術應用、監管要求、醫療基礎設施、病患就醫途徑和區域醫療服務模式等方面進行三角檢驗。

結論

糖尿病注射筆正從單純的便利給藥裝置發展成為支援更安全、更個人化慢性病管理的互聯平台。糖尿病盛行率的上升、注射療法使用量的增加、對劑量精準度的日益關注以及對居家照護需求的成長，都為市場成長奠定了堅實的基礎。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 糖尿病注射筆市場：依產品類型分類

  • 預填充筆
  • 可重複使用的筆

第8章 糖尿病注射筆市場：依技術分類

  • 傳統筆
  • 智慧筆

第9章：糖尿病注射筆市場：依治療類型分類

  • 長效胰島素筆
  • 預混合料胰島素筆
  • 速效胰島素筆

第10章：糖尿病注射筆市場：依最終用戶分類

  • 診所
  • 居家照護環境
  • 醫院
  • 藥局

第11章 糖尿病注射筆市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章 糖尿病注射筆市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章 糖尿病注射筆市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 糖尿病注射筆市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • AstraZeneca PLC
  • Becton, Dickinson and Company
  • Biocon Limited
  • Eli Lilly and Company
  • Emperra GmbH
  • Gan & Lee Pharmaceuticals Co., Ltd.
  • Gerresheimer AG
  • Haselmeier GmbH
  • HTL-Strefa SA
  • Jiangsu Delfu Medical Devices Co., Ltd.
  • Lupin Limited
  • Medmix AG
  • Merck KGaA
  • Nemera France SAS
  • Novo Nordisk A/S
  • Owen Mumford Limited
  • Pfizer Inc.
  • Sanofi SA
  • SHL Medical AG
  • Terumo Corporation
  • Teva Pharmaceutical Industries
  • Wanhai Medical Instruments
  • Wockhardt Ltd.
  • Ypsomed Holding AG
Product Code: MRR-4348D129FA0E

The Diabetes Injection Pens Market is projected to grow by USD 28.93 billion at a CAGR of 6.60% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 18.50 billion
Estimated Year [2026] USD 19.60 billion
Forecast Year [2032] USD 28.93 billion
CAGR (%) 6.60%

Diabetes injection pens are becoming a core delivery platform for insulin and other injectable diabetes therapies as health systems respond to rising disease prevalence, treatment intensification, and the need for safer self-administration. The International Diabetes Federation estimates that 537 million adults were living with diabetes in 2021, with the total projected to reach 643 million by 2030 and 783 million by 2045, creating sustained demand for reliable, patient-friendly injection devices.

The market is shaped by disposable insulin pens, reusable pens, connected smart pens, pen needles, and training ecosystems that support dose accuracy, adherence, and patient confidence. Adoption is supported by the shift from clinic-centered care to home-based chronic disease management, while affordability, reimbursement, cold-chain logistics, prescribing practices, and device waste remain decisive factors for manufacturers, payers, providers, and patients.

Transformative Shifts in the Diabetes Injection Pens Landscape

The diabetes injection pens landscape is moving from conventional mechanical devices toward connected, patient-centered delivery systems. Smart pens that record dose timing and quantity are increasingly aligned with continuous glucose monitoring, mobile health apps, and clinician dashboards, enabling more actionable diabetes management without requiring every patient to use an insulin pump.

At the same time, broader use of long-acting insulin analogs, biosimilar insulin launches, and injectable GLP-1 therapies is changing competitive dynamics. Procurement decisions are no longer based only on drug formulation; they increasingly include device ergonomics, dose-memory features, needle compatibility, dose titration support, sustainability profile, and integration with digital diabetes care pathways.

Cumulative Impact of Artificial Intelligence on Diabetes Injection Pens

Artificial intelligence is adding cumulative value across diabetes injection pen development, commercialization, and use. In connected care, AI-enabled analytics can help identify missed doses, irregular dosing patterns, and glucose variability when combined with patient-generated data from glucose meters or continuous glucose monitors. These capabilities support more personalized clinical conversations and may reduce therapeutic inertia when used under appropriate medical supervision.

AI is also influencing manufacturing quality control, demand planning, inventory optimization, pharmacovigilance, and post-market surveillance. For diabetes injection pen companies, the priority is to apply AI within validated, privacy-compliant workflows because dosing recommendations, cybersecurity, algorithm transparency, clinical validation, and regulatory accountability remain critical to patient safety and market trust.

Key Regional Insights for Diabetes Injection Pens

Asia-Pacific represents one of the most important growth environments for diabetes injection pens due to its large diabetes population, expanding middle class, and increasing diagnosis rates in China, India, Japan, South Korea, and Australia. The International Diabetes Federation identifies the Western Pacific and South-East Asia among the regions with the largest numbers of adults living with diabetes, making access to insulin pens, pen needles, and patient education a major healthcare priority. North America remains a high-value market supported by advanced endocrinology care, strong use of analog insulin and GLP-1 therapies, pharmacy benefit management, and rapid adoption of connected diabetes devices.

Europe benefits from mature reimbursement systems, established clinical guidelines, and strong emphasis on device safety, usability, data protection, and sustainability, while Latin America is progressing through broader access to insulin, private healthcare expansion, and public procurement initiatives in countries such as Brazil and Mexico. The Middle East is seeing demand linked to high diabetes prevalence, obesity-related metabolic risk, and investment in specialized diabetes centers, while Africa remains highly access-sensitive, with affordability, availability of trained healthcare workers, reliable cold-chain logistics, and continuity of insulin supply shaping diabetes injection pen adoption.

Key Group Insights Across ASEAN, GCC, EU, BRICS, G7, and NATO

Within ASEAN, diabetes injection pen demand is supported by urbanization, expanding private healthcare, and government efforts to address noncommunicable diseases, although affordability and reimbursement vary sharply across member states. The GCC shows strong adoption potential due to high diabetes burden, advanced hospital infrastructure, national digital health strategies, and growing investment in specialty care models that support connected diabetes management.

The European Union emphasizes safety, quality, data protection, and sustainability, making regulatory compliance, post-market surveillance, and environmental design increasingly important for pen manufacturers. BRICS countries offer scale and long-term access potential, particularly through local manufacturing, public tenders, biosimilar insulin availability, and large populations requiring chronic diabetes care. G7 markets remain innovation-led, with stronger uptake of smart pens, premium pen needles, and integrated digital health solutions, while NATO member countries largely overlap with developed healthcare systems where supply-chain resilience, cybersecurity, device traceability, and medical device security are becoming more prominent procurement considerations.

Key Country Insights for Diabetes Injection Pens

The United States is characterized by high therapy innovation, broad use of injectable diabetes medicines, and a strong focus on affordability, formulary access, and out-of-pocket cost management. Canada combines universal healthcare principles with provincial reimbursement variation, while Mexico and Brazil show rising demand through public health programs, private-sector growth, and expanding diabetes diagnosis. In Europe, the United Kingdom, Germany, France, Italy, and Spain benefit from guideline-based diabetes care, structured reimbursement, and mature pharmacy networks, whereas Russia's market is influenced by localization, procurement policy, import substitution priorities, and supply continuity.

China and India are central to global volume growth due to large diabetes populations and expanding access to insulin and injectable therapies, with public health initiatives and local production capacity shaping adoption. Japan, South Korea, and Australia show high expectations for device quality, patient training, safety, and digital integration, supported by advanced healthcare systems and established diabetes management pathways. Across these countries, manufacturers that align diabetes injection pens with local reimbursement, language-specific education, culturally relevant training, pen-needle availability, cold-chain reliability, and clinician workflows are better positioned for durable adoption.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize device portfolios that balance affordability, usability, dose accuracy, injection comfort, and digital readiness. Companies can strengthen adoption by investing in human-factors engineering, multilingual patient education, clinician training, and device designs suitable for elderly patients and people with dexterity, vision, or numeracy limitations.

Manufacturers should also build payer evidence around adherence, treatment persistence, reduced dosing errors, fewer missed injections, and patient satisfaction rather than relying only on device preference claims. Strategic partnerships with glucose monitoring providers, diabetes clinics, pharmacies, telehealth platforms, and care-management programs can accelerate connected pen ecosystems, while localized manufacturing, resilient sourcing, validated cybersecurity, and sustainable device design can reduce exposure to supply disruptions and regulatory risk.

Research Methodology

This executive assessment is based on secondary research from recognized public health, regulatory, and industry sources, including international diabetes prevalence data, medical device guidance, reimbursement trends, clinical practice patterns, and approved injectable diabetes therapy information. The methodology emphasizes triangulation across epidemiology, technology adoption, regulatory requirements, healthcare infrastructure, patient-access conditions, and regional care-delivery models.

Insights were developed through qualitative market interpretation, competitive landscape review, regional demand analysis, and evaluation of device-use factors such as adherence, dose recording, safety, training burden, injection comfort, interoperability, cybersecurity, and lifecycle sustainability. The approach avoids unverified market sizing claims and focuses on evidence-backed drivers shaping diabetes injection pen adoption.

Conclusion

Diabetes injection pens are advancing from convenient drug-delivery devices to connected platforms that support safer, more personalized chronic disease management. Rising diabetes prevalence, expanding use of injectable therapies, greater attention to dose accuracy, and growing demand for home-based care create a durable foundation for market development.

The strongest opportunities will emerge where manufacturers combine clinically trusted devices, affordable access, digital interoperability, sustainable design, dependable supply chains, and region-specific commercialization strategies. Companies that address both patient experience and healthcare-system constraints will be best positioned to lead the next phase of diabetes injection pen adoption.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Diabetes Injection Pens Market, by Product Type

  • 7.1. Prefilled Pens
  • 7.2. Reusable Pens

8. Diabetes Injection Pens Market, by Technology

  • 8.1. Conventional Pens
  • 8.2. Smart Pens

9. Diabetes Injection Pens Market, by Therapy Type

  • 9.1. Long-Acting Insulin Pens
  • 9.2. Premixed Insulin Pens
  • 9.3. Rapid-Acting Insulin Pens

10. Diabetes Injection Pens Market, by End User

  • 10.1. Clinics
  • 10.2. Homecare Settings
  • 10.3. Hospitals
  • 10.4. Pharmacies

11. Diabetes Injection Pens Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacies
  • 11.3. Retail Pharmacies

12. Diabetes Injection Pens Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Diabetes Injection Pens Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Diabetes Injection Pens Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Concentration Analysis, 2025
    • 15.1.1. Concentration Ratio (CR)
    • 15.1.2. Herfindahl Hirschman Index (HHI)
  • 15.2. Recent Developments & Impact Analysis, 2025
  • 15.3. Product Portfolio Analysis, 2025
  • 15.4. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. AstraZeneca PLC
  • 16.2. Becton, Dickinson and Company
  • 16.3. Biocon Limited
  • 16.4. Eli Lilly and Company
  • 16.5. Emperra GmbH
  • 16.6. Gan & Lee Pharmaceuticals Co., Ltd.
  • 16.7. Gerresheimer AG
  • 16.8. Haselmeier GmbH
  • 16.9. HTL-Strefa S.A.
  • 16.10. Jiangsu Delfu Medical Devices Co., Ltd.
  • 16.11. Lupin Limited
  • 16.12. Medmix AG
  • 16.13. Merck KGaA
  • 16.14. Nemera France SAS
  • 16.15. Novo Nordisk A/S
  • 16.16. Owen Mumford Limited
  • 16.17. Pfizer Inc.
  • 16.18. Sanofi S.A.
  • 16.19. SHL Medical AG
  • 16.20. Terumo Corporation
  • 16.21. Teva Pharmaceutical Industries
  • 16.22. Wanhai Medical Instruments
  • 16.23. Wockhardt Ltd.
  • 16.24. Ypsomed Holding AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL DIABETES INJECTION PENS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL DIABETES INJECTION PENS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL DIABETES INJECTION PENS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL DIABETES INJECTION PENS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL DIABETES INJECTION PENS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL DIABETES INJECTION PENS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL DIABETES INJECTION PENS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL DIABETES INJECTION PENS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL DIABETES INJECTION PENS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DIABETES INJECTION PENS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL DIABETES INJECTION PENS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL DIABETES INJECTION PENS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL DIABETES INJECTION PENS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL DIABETES INJECTION PENS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL DIABETES INJECTION PENS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL DIABETES INJECTION PENS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL DIABETES INJECTION PENS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL DIABETES INJECTION PENS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL DIABETES INJECTION PENS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL DIABETES INJECTION PENS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL DIABETES INJECTION PENS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL DIABETES INJECTION PENS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL DIABETES INJECTION PENS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DIABETES INJECTION PENS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DIABETES INJECTION PENS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PREFILLED PENS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PREFILLED PENS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PREFILLED PENS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL REUSABLE PENS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL REUSABLE PENS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL REUSABLE PENS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DIABETES INJECTION PENS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CONVENTIONAL PENS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CONVENTIONAL PENS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CONVENTIONAL PENS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL SMART PENS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL SMART PENS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL SMART PENS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DIABETES INJECTION PENS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL LONG-ACTING INSULIN PENS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL LONG-ACTING INSULIN PENS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL LONG-ACTING INSULIN PENS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PREMIXED INSULIN PENS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PREMIXED INSULIN PENS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PREMIXED INSULIN PENS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL RAPID-ACTING INSULIN PENS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL RAPID-ACTING INSULIN PENS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL RAPID-ACTING INSULIN PENS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DIABETES INJECTION PENS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DIABETES INJECTION PENS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DIABETES INJECTION PENS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC DIABETES INJECTION PENS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC DIABETES INJECTION PENS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC DIABETES INJECTION PENS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC DIABETES INJECTION PENS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC DIABETES INJECTION PENS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC DIABETES INJECTION PENS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 56. NORTH AMERICA DIABETES INJECTION PENS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 57. NORTH AMERICA DIABETES INJECTION PENS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA DIABETES INJECTION PENS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 59. NORTH AMERICA DIABETES INJECTION PENS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 60. NORTH AMERICA DIABETES INJECTION PENS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA DIABETES INJECTION PENS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 62. LATIN AMERICA DIABETES INJECTION PENS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 63. LATIN AMERICA DIABETES INJECTION PENS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 64. LATIN AMERICA DIABETES INJECTION PENS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 65. LATIN AMERICA DIABETES INJECTION PENS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 66. LATIN AMERICA DIABETES INJECTION PENS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 67. LATIN AMERICA DIABETES INJECTION PENS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE DIABETES INJECTION PENS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE DIABETES INJECTION PENS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE DIABETES INJECTION PENS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE DIABETES INJECTION PENS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE DIABETES INJECTION PENS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE DIABETES INJECTION PENS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 74. MIDDLE EAST DIABETES INJECTION PENS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 75. MIDDLE EAST DIABETES INJECTION PENS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. MIDDLE EAST DIABETES INJECTION PENS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 77. MIDDLE EAST DIABETES INJECTION PENS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. MIDDLE EAST DIABETES INJECTION PENS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 79. MIDDLE EAST DIABETES INJECTION PENS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 80. AFRICA DIABETES INJECTION PENS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 81. AFRICA DIABETES INJECTION PENS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. AFRICA DIABETES INJECTION PENS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 83. AFRICA DIABETES INJECTION PENS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. AFRICA DIABETES INJECTION PENS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. AFRICA DIABETES INJECTION PENS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL DIABETES INJECTION PENS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. ASEAN DIABETES INJECTION PENS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 88. ASEAN DIABETES INJECTION PENS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. ASEAN DIABETES INJECTION PENS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 90. ASEAN DIABETES INJECTION PENS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. ASEAN DIABETES INJECTION PENS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. ASEAN DIABETES INJECTION PENS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 93. GCC DIABETES INJECTION PENS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 94. GCC DIABETES INJECTION PENS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. GCC DIABETES INJECTION PENS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 96. GCC DIABETES INJECTION PENS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. GCC DIABETES INJECTION PENS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. GCC DIABETES INJECTION PENS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPEAN UNION DIABETES INJECTION PENS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPEAN UNION DIABETES INJECTION PENS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPEAN UNION DIABETES INJECTION PENS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPEAN UNION DIABETES INJECTION PENS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPEAN UNION DIABETES INJECTION PENS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPEAN UNION DIABETES INJECTION PENS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 105. BRICS DIABETES INJECTION PENS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 106. BRICS DIABETES INJECTION PENS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. BRICS DIABETES INJECTION PENS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 108. BRICS DIABETES INJECTION PENS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. BRICS DIABETES INJECTION PENS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. BRICS DIABETES INJECTION PENS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. G7 DIABETES INJECTION PENS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 112. G7 DIABETES INJECTION PENS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. G7 DIABETES INJECTION PENS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 114. G7 DIABETES INJECTION PENS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. G7 DIABETES INJECTION PENS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. G7 DIABETES INJECTION PENS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 117. NATO DIABETES INJECTION PENS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 118. NATO DIABETES INJECTION PENS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. NATO DIABETES INJECTION PENS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 120. NATO DIABETES INJECTION PENS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. NATO DIABETES INJECTION PENS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. NATO DIABETES INJECTION PENS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL DIABETES INJECTION PENS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. UNITED STATES DIABETES INJECTION PENS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 125. UNITED STATES DIABETES INJECTION PENS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. UNITED STATES DIABETES INJECTION PENS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 127. UNITED STATES DIABETES INJECTION PENS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. UNITED STATES DIABETES INJECTION PENS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. UNITED STATES DIABETES INJECTION PENS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 130. CANADA DIABETES INJECTION PENS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 131. CANADA DIABETES INJECTION PENS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. CANADA DIABETES INJECTION PENS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 133. CANADA DIABETES INJECTION PENS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. CANADA DIABETES INJECTION PENS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. CANADA DIABETES INJECTION PENS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 136. MEXICO DIABETES INJECTION PENS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 137. MEXICO DIABETES INJECTION PENS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. MEXICO DIABETES INJECTION PENS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 139. MEXICO DIABETES INJECTION PENS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. MEXICO DIABETES INJECTION PENS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. MEXICO DIABETES INJECTION PENS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 142. BRAZIL DIABETES INJECTION PENS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 143. BRAZIL DIABETES INJECTION PENS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. BRAZIL DIABETES INJECTION PENS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 145. BRAZIL DIABETES INJECTION PENS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. BRAZIL DIABETES INJECTION PENS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. BRAZIL DIABETES INJECTION PENS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. UNITED KINGDOM DIABETES INJECTION PENS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 149. UNITED KINGDOM DIABETES INJECTION PENS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. UNITED KINGDOM DIABETES INJECTION PENS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 151. UNITED KINGDOM DIABETES INJECTION PENS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. UNITED KINGDOM DIABETES INJECTION PENS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. UNITED KINGDOM DIABETES INJECTION PENS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 154. GERMANY DIABETES INJECTION PENS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 155. GERMANY DIABETES INJECTION PENS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. GERMANY DIABETES INJECTION PENS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 157. GERMANY DIABETES INJECTION PENS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. GERMANY DIABETES INJECTION PENS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. GERMANY DIABETES INJECTION PENS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 160. FRANCE DIABETES INJECTION PENS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 161. FRANCE DIABETES INJECTION PENS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. FRANCE DIABETES INJECTION PENS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 163. FRANCE DIABETES INJECTION PENS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. FRANCE DIABETES INJECTION PENS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. FRANCE DIABETES INJECTION PENS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 166. RUSSIA DIABETES INJECTION PENS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 167. RUSSIA DIABETES INJECTION PENS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. RUSSIA DIABETES INJECTION PENS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 169. RUSSIA DIABETES INJECTION PENS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. RUSSIA DIABETES INJECTION PENS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. RUSSIA DIABETES INJECTION PENS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 172. ITALY DIABETES INJECTION PENS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 173. ITALY DIABETES INJECTION PENS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. ITALY DIABETES INJECTION PENS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 175. ITALY DIABETES INJECTION PENS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. ITALY DIABETES INJECTION PENS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. ITALY DIABETES INJECTION PENS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 178. SPAIN DIABETES INJECTION PENS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 179. SPAIN DIABETES INJECTION PENS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. SPAIN DIABETES INJECTION PENS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 181. SPAIN DIABETES INJECTION PENS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. SPAIN DIABETES INJECTION PENS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. SPAIN DIABETES INJECTION PENS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 184. CHINA DIABETES INJECTION PENS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 185. CHINA DIABETES INJECTION PENS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. CHINA DIABETES INJECTION PENS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 187. CHINA DIABETES INJECTION PENS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. CHINA DIABETES INJECTION PENS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. CHINA DIABETES INJECTION PENS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 190. INDIA DIABETES INJECTION PENS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 191. INDIA DIABETES INJECTION PENS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. INDIA DIABETES INJECTION PENS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 193. INDIA DIABETES INJECTION PENS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. INDIA DIABETES INJECTION PENS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. INDIA DIABETES INJECTION PENS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 196. JAPAN DIABETES INJECTION PENS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 197. JAPAN DIABETES INJECTION PENS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. JAPAN DIABETES INJECTION PENS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 199. JAPAN DIABETES INJECTION PENS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. JAPAN DIABETES INJECTION PENS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. JAPAN DIABETES INJECTION PENS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 202. AUSTRALIA DIABETES INJECTION PENS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 203. AUSTRALIA DIABETES INJECTION PENS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. AUSTRALIA DIABETES INJECTION PENS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 205. AUSTRALIA DIABETES INJECTION PENS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. AUSTRALIA DIABETES INJECTION PENS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. AUSTRALIA DIABETES INJECTION PENS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 208. SOUTH KOREA DIABETES INJECTION PENS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 209. SOUTH KOREA DIABETES INJECTION PENS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. SOUTH KOREA DIABETES INJECTION PENS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 211. SOUTH KOREA DIABETES INJECTION PENS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. SOUTH KOREA DIABETES INJECTION PENS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. SOUTH KOREA DIABETES INJECTION PENS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)